Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Kevin T Conroy. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Kevin T Conroy har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:ALGN / Align Technology, Inc. | Director | 1 808 |
US:EXAS / Exact Sciences Corporation | President and CEO, Director | 0 |
US:ADPT / Adaptive Biotechnologies Corporation | Director | 22 968 |
US:EPZM / Epizyme Inc | Director | 0 |
US:US83444K1135 / SomaLogic Inc | Director | 0 |
Director | 0 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Kevin T Conroy. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp ADPT / Adaptive Biotechnologies Corporation - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i ADPT / Adaptive Biotechnologies Corporation. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i ADPT / Adaptive Biotechnologies Corporation. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Kevin T Conroy som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-05-22 |
|
4 | ALGN |
ALIGN TECHNOLOGY INC
Common Stock |
M - Exercise | 1 148 | 1 808 | 173,94 | ||||
2025-04-29 |
|
5/A | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −22 063 | 0 | −100,00 | ||||
2025-04-29 |
|
5/A | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −43 126 | 22 063 | −66,16 | ||||
2025-04-29 |
|
5/A | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | 43 126 | 893 818 | 5,07 | ||||
2025-04-29 |
|
5/A | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −28 660 | 850 692 | −3,26 | ||||
2025-04-29 |
|
5 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −163 000 | 602 120 | −21,30 | ||||
2025-04-29 |
|
5 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −74 599 | 779 944 | −8,73 | ||||
2025-03-10 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −48 929 | 1 154 340 | −4,07 | 47,06 | −2 302 599 | 54 323 240 | |
2025-03-10 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 66 723 | 1 203 269 | 5,87 | 22,38 | 1 493 261 | 26 929 160 | |
2025-03-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −10 419 | 1 136 546 | −0,91 | 47,82 | −498 237 | 54 349 630 | |
2025-03-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 22 167 | 1 146 965 | 1,97 | ||||
2025-03-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −8 528 | 1 124 798 | −0,75 | 47,82 | −407 809 | 53 787 840 | |
2025-03-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 18 143 | 1 133 326 | 1,63 | ||||
2025-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −6 195 | 1 115 183 | −0,55 | 51,28 | −317 680 | 57 186 584 | |
2025-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 13 180 | 1 121 378 | 1,19 | ||||
2025-02-21 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −21 140 | 1 108 198 | −1,87 | 50,48 | −1 067 147 | 55 941 835 | |
2025-02-21 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 48 044 | 1 129 338 | 4,44 | ||||
2025-02-21 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −3 271 | 1 081 294 | −0,30 | 49,63 | −162 340 | 53 664 621 | |
2025-02-21 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 10 374 | 1 084 565 | 0,97 | ||||
2024-11-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
P - Purchase | 19 500 | 1 074 191 | 1,85 | 51,35 | 1 001 325 | 55 159 708 | |
2024-05-24 |
|
4 | ALGN |
ALIGN TECHNOLOGY INC
Common Stock |
M - Exercise | 660 | 660 | |||||
2024-05-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −1 155 | 1 156 191 | −0,10 | 60,15 | −69 473 | 69 544 889 |
2024-05-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 708 | 1 157 346 | 0,06 | 30,02 | 21 254 | 34 743 527 | |
2024-05-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 2 489 | 1 156 638 | 0,22 | ||||
2024-03-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −8 271 | 1 299 496 | −0,63 | 59,32 | −490 636 | 77 086 103 |
2024-03-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 18 143 | 1 307 767 | 1,41 | ||||
2024-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −6 263 | 1 289 624 | −0,48 | 56,89 | −356 302 | 73 366 709 |
2024-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 13 181 | 1 295 887 | 1,03 | ||||
2024-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −61 560 | 1 282 706 | −4,58 | 57,53 | −3 541 547 | 73 794 076 | |
2024-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 102 837 | 1 344 266 | 8,28 | 13,96 | 1 435 605 | 18 765 953 | |
2024-02-23 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −11 565 | 1 241 429 | −0,92 | 59,78 | −691 356 | 74 212 626 |
2024-02-23 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 23 238 | 1 252 994 | 1,89 | ||||
2024-02-22 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −4 975 | 1 229 756 | −0,40 | 61,50 | −305 962 | 75 629 994 |
2024-02-22 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 10 374 | 1 234 731 | 0,85 | ||||
2024-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −14 791 | 1 224 357 | −1,19 | 61,43 | −908 611 | 75 212 251 |
2024-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 31 133 | 1 239 148 | 2,58 | ||||
2024-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 709 | 1 208 015 | 0,06 | 30,02 | 21 284 | 36 264 610 | |
2023-03-08 |
|
4 | ADPT |
Adaptive Biotechnologies Corp
Common Stock |
A - Award | 14 775 | 22 968 | 180,34 | ||||
2023-03-01 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −10 416 | 1 207 306 | −0,86 | 61,12 | −636 626 | 73 790 543 |
2023-03-01 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 9 312 | 1 217 722 | 0,77 | ||||
2023-03-01 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 13 180 | 1 208 410 | 1,10 | ||||
2023-02-23 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −4 764 | 1 195 230 | −0,40 | 62,72 | −298 798 | 74 964 826 |
2023-02-23 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 10 374 | 1 199 994 | 0,87 | ||||
2023-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −14 617 | 1 189 620 | −1,21 | 65,59 | −958 729 | 78 027 176 | |
2023-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 31 132 | 1 204 237 | 2,65 | ||||
2023-02-14 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −4 527 | 1 173 105 | −0,38 | 64,55 | −292 218 | 75 723 928 |
2023-02-14 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 9 705 | 1 177 632 | 0,83 | ||||
2022-08-16 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
D - Sale to Issuer | −8 994 | 0 | −100,00 | ||||
2022-08-16 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
D - Sale to Issuer | −53 324 | 8 994 | −85,57 | ||||
2022-07-06 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −7 | 1 167 927 | 0,00 | 40,75 | −285 | 47 593 025 |
2022-07-06 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 328 | 1 167 934 | 0,03 | 47,41 | 15 550 | 55 371 751 | |
2022-07-05 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 10 204 | 62 318 | 19,58 | 1,47 | 15 000 | 91 607 | |
2022-05-19 |
|
4 | EPZM |
Epizyme, Inc.
Stock Option (Right to Buy) |
A - Award | 41 006 | 41 006 | |||||
2022-05-19 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 8 994 | 52 114 | 20,86 | ||||
2022-04-01 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 13 043 | 43 120 | 43,37 | 1,15 | 14 999 | 49 588 | |
2022-03-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −2 253 | 66 047 | −3,30 | ||||
2022-03-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −4 612 | 235 388 | −1,92 | ||||
2022-03-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −229 757 | 0 | −100,00 | ||||
2022-03-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 2 253 | 1 167 606 | 0,19 | 44,37 | 99 966 | 51 806 678 | |
2022-03-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 4 612 | 1 165 353 | 0,40 | 21,68 | 99 988 | 25 264 853 | |
2022-03-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 229 757 | 1 160 741 | 24,68 | 5,70 | 1 309 615 | 6 616 224 | |
2022-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −14 299 | 930 984 | −1,51 | 76,69 | −1 096 590 | 71 397 163 |
2022-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −9 312 | 9 312 | −50,00 | ||||
2022-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 575 | 0 | −100,00 | ||||
2022-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 9 312 | 945 283 | 0,99 | ||||
2022-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 575 | 935 971 | 2,25 | ||||
2022-03-01 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 52 722 | 52 722 | |||||
2022-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −27 126 | 915 396 | −2,88 | 70,10 | −1 901 533 | 64 169 260 |
2022-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Performance Stock Units |
M - Exercise | −58 643 | 0 | −100,00 | ||||
2022-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 58 643 | 942 522 | 6,63 | ||||
2022-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −5 188 | 883 879 | −0,58 | 69,05 | −358 231 | 61 031 845 |
2022-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −10 373 | 31 122 | −25,00 | ||||
2022-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 10 373 | 889 067 | 1,18 | ||||
2022-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −14 409 | 878 694 | −1,61 | 79,55 | −1 146 236 | 69 900 108 |
2022-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −31 133 | 62 265 | −33,33 | ||||
2022-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −96 758 | 0 | −100,00 | ||||
2022-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −94 425 | 0 | −100,00 | ||||
2022-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 31 133 | 893 103 | 3,61 | 78,33 | 2 438 648 | 69 956 758 | |
2022-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 96 758 | 861 970 | 12,64 | 10,82 | 1 046 922 | 9 326 515 | |
2022-02-16 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 94 425 | 765 212 | 14,08 | 9,07 | 856 435 | 6 940 473 | |
2022-01-28 |
|
4 | ADPT |
Adaptive Biotechnologies Corp
Stock Option (Right to Buy) |
A - Award | 16 722 | 16 722 | |||||
2022-01-28 |
|
4 | ADPT |
Adaptive Biotechnologies Corp
Common Stock |
A - Award | 6 689 | 8 193 | 444,75 | ||||
2022-01-19 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 6 407 | 670 787 | 0,96 | ||||
2022-01-04 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 6 000 | 30 077 | 24,92 | 2,50 | 15 000 | 75 192 | |
2021-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −16 922 | 664 380 | −2,48 | 93,88 | −1 588 637 | 62 371 994 |
2021-10-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −17 078 | 681 302 | −2,45 | 93,64 | −1 599 184 | 63 797 119 |
2021-10-01 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 2 930 | 24 077 | 13,86 | 5,12 | 15 002 | 123 274 | |
2021-09-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −18 978 | 698 380 | −2,65 | 104,42 | −1 981 683 | 72 924 840 |
2021-09-03 |
|
4 | SLGCW |
SomaLogic, Inc.
Class B Common Stock |
M - Exercise | −25 000 | 0 | −100,00 | ||||
2021-09-03 |
|
4 | SLGCW |
SomaLogic, Inc.
Warrants to purchase Class A Common Stock (right to buy) |
A - Award | 166 666 | 166 666 | |||||
2021-09-03 |
|
4 | SLGCW |
SomaLogic, Inc.
Class A Common Stock |
J - Other | 25 000 | 25 000 | |||||
2021-08-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −19 970 | 717 358 | −2,71 | 107,50 | −2 146 775 | 77 115 985 |
2021-07-06 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −7 784 | 737 328 | −1,04 | 123,43 | −960 779 | 91 008 395 |
2021-07-01 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 1 805 | 21 147 | 9,33 | 8,31 | 15 000 | 175 732 | |
2021-06-15 |
|
4 | EPZM |
Epizyme, Inc.
Stock Option (Right to Buy) |
A - Award | 40 559 | 40 559 | |||||
2021-06-15 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 8 060 | 19 342 | 71,44 | ||||
2021-06-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −12 384 | 745 112 | −1,63 | 111,00 | −1 374 624 | 82 707 432 |
2021-05-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −19 240 | 757 496 | −2,48 | 131,09 | −2 522 172 | 99 300 151 |
2021-05-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 328 | 776 736 | 0,04 | 64,74 | 21 235 | 50 285 889 | |
2021-04-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −22 755 | 776 408 | −2,85 | 132,30 | −3 010 486 | 102 718 778 |
2021-04-01 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 1 723 | 11 282 | 18,02 | 8,71 | 15 007 | 98 266 | |
2021-03-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 796 | 799 163 | −1,21 | 138,42 | −1 355 962 | 110 620 142 |
2021-03-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 575 | 20 575 | −50,00 | ||||
2021-03-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 575 | 808 959 | 2,61 | ||||
2021-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −26 958 | 788 384 | −3,31 | 136,79 | −3 687 585 | 107 843 047 |
2021-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −4 335 | 815 342 | −0,53 | 137,44 | −595 802 | 112 060 604 |
2021-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −9 312 | 18 624 | −33,33 | ||||
2021-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 9 312 | 819 677 | 1,15 | ||||
2021-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −16 420 | 810 365 | −1,99 | 136,30 | −2 238 046 | 110 452 750 |
2021-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −34 325 | 0 | −100,00 | ||||
2021-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 34 325 | 826 785 | 4,33 | ||||
2021-02-23 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 41 495 | 41 495 | |||||
2021-02-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −15 825 | 792 460 | −1,96 | 142,66 | −2 257 594 | 113 052 344 |
2021-02-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −31 132 | 93 398 | −25,00 | ||||
2021-02-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 31 132 | 808 285 | 4,01 | ||||
2021-02-17 |
|
4 | ADPT |
Adaptive Biotechnologies Corp
Stock Option (Right to Buy) |
A - Award | 3 759 | 3 759 | |||||
2021-02-17 |
|
4 | ADPT |
Adaptive Biotechnologies Corp
Common Stock |
A - Award | 1 504 | 1 504 | |||||
2021-02-09 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −17 543 | 229 757 | −7,09 | ||||
2021-02-09 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 17 543 | 777 153 | 2,31 | 5,70 | 99 995 | 4 429 772 | |
2021-02-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −30 344 | 759 610 | −3,84 | 138,07 | −4 189 596 | 104 879 353 |
2021-02-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −35 750 | 789 954 | −4,33 | ||||
2021-01-07 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −31 814 | 825 704 | −3,71 | 128,74 | −4 095 734 | 106 301 133 |
2021-01-05 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 1 024 | 9 559 | 12,00 | 10,86 | 11 121 | 103 811 | |
2020-12-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −100 | 857 518 | −0,01 | 126,59 | −12 659 | 108 553 204 |
2020-12-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −100 | 857 618 | −0,01 | 126,49 | −12 649 | 108 480 101 |
2020-12-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −7 043 | 857 718 | −0,81 | 125,92 | −886 855 | 108 003 851 |
2020-12-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −10 840 | 864 761 | −1,24 | 124,88 | −1 353 699 | 107 991 354 |
2020-12-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −7 776 | 875 601 | −0,88 | 124,03 | −964 457 | 108 600 792 |
2020-12-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −2 918 | 883 377 | −0,33 | 122,91 | −358 651 | 108 575 867 |
2020-12-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −1 800 | 886 295 | −0,20 | 122,05 | −219 690 | 108 172 305 |
2020-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −400 | 888 095 | −0,05 | 124,71 | −49 884 | 110 754 327 |
2020-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −600 | 888 495 | −0,07 | 123,45 | −74 070 | 109 684 708 |
2020-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 577 | 889 095 | −1,07 | 122,33 | −1 171 554 | 108 762 991 |
2020-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −10 229 | 898 672 | −1,13 | 121,52 | −1 243 028 | 109 206 621 |
2020-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −6 512 | 908 901 | −0,71 | 120,45 | −784 370 | 109 477 125 |
2020-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −1 108 | 915 413 | −0,12 | 119,18 | −132 051 | 109 098 921 |
2020-11-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −4 393 | 916 521 | −0,48 | 118,32 | −519 780 | 108 442 765 |
2020-10-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −1 136 | 920 914 | −0,12 | 105,20 | −119 507 | 96 880 153 |
2020-10-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −5 200 | 922 050 | −0,56 | 104,70 | −544 440 | 96 538 635 |
2020-10-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 391 | 927 250 | −1,00 | 103,57 | −972 626 | 96 035 282 |
2020-10-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −11 698 | 936 641 | −1,23 | 102,86 | −1 203 256 | 96 342 893 |
2020-10-01 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 933 | 8 535 | 12,27 | 11,93 | 11 131 | 101 823 | |
2020-09-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −19 927 | 948 339 | −2,06 | 75,03 | −1 495 123 | 71 153 875 |
2020-08-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −198 | 968 266 | −0,02 | 95,00 | −18 810 | 91 985 270 |
2020-08-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −25 000 | 968 464 | −2,52 | 93,79 | −2 344 750 | 90 832 239 |
2020-08-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 501 | 993 464 | 0,05 | 42,44 | 21 262 | 42 162 612 | |
2020-07-06 |
|
4 | ARYA |
ARYA SCIENCES ACQUISITION CORP.
Class B Ordinary Shares |
D - Sale to Issuer | −30 000 | 0 | −100,00 | ||||
2020-07-01 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 693 | 7 602 | 10,03 | 16,06 | 11 130 | 122 088 | |
2020-06-02 |
|
4 | EPZM |
Epizyme, Inc.
Stock Option (Right to Buy) |
A - Award | 14 013 | 14 013 | |||||
2020-04-02 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 717 | 6 909 | 11,58 | 15,51 | 11 121 | 107 159 | |
2020-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 750 | 992 963 | −0,97 | 80,17 | −781 658 | 79 605 844 |
2020-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 575 | 41 150 | −33,33 | ||||
2020-03-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 575 | 1 002 713 | 2,09 | ||||
2020-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −13 875 | 982 138 | −1,39 | 80,27 | −1 113 746 | 78 836 217 |
2020-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −9 312 | 27 936 | −25,00 | ||||
2020-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 025 | 0 | −100,00 | ||||
2020-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 9 312 | 996 013 | 0,94 | ||||
2020-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 025 | 986 701 | 2,07 | ||||
2020-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −18 115 | 966 676 | −1,84 | 85,11 | −1 541 768 | 82 273 794 |
2020-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −34 325 | 34 325 | −50,00 | ||||
2020-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 34 325 | 984 791 | 3,61 | ||||
2020-02-18 |
|
4 | ADPT |
Adaptive Biotechnologies Corp
Stock Option (Right to Buy) |
A - Award | 8 888 | 8 888 | |||||
2020-02-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 124 530 | 124 530 | |||||
2020-02-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 100 916 | 100 916 | |||||
2020-02-14 |
|
5 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | 21 729 | 21 729 | |||||
2020-02-14 |
|
5 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | 21 730 | 21 730 | |||||
2020-02-14 |
|
5 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | 21 730 | 21 730 | |||||
2020-02-14 |
|
5 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −65 189 | 0 | −100,00 | ||||
2020-01-03 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 452 | 6 192 | 7,87 | 24,60 | 11 119 | 152 323 | |
2019-12-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −4 277 | 66 723 | −6,02 | ||||
2019-12-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −7 163 | 102 837 | −6,51 | ||||
2019-12-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 4 277 | 950 466 | 0,45 | 23,38 | 99 996 | 22 221 895 | |
2019-12-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 7 163 | 946 189 | 0,76 | 13,96 | 99 995 | 13 208 798 | |
2019-12-18 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 500 | 939 026 | 0,05 | 42,44 | 21 220 | 39 852 263 | |
2019-10-02 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 1 078 | 5 740 | 23,12 | 10,32 | 11 125 | 59 237 | |
2019-07-02 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 887 | 4 662 | 23,50 | 12,55 | 11 132 | 58 508 | |
2019-06-07 |
|
4 | EPZM |
Epizyme, Inc.
Stock Option (Right to Buy) |
A - Award | 17 633 | 17 633 | |||||
2019-06-07 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 897 | 3 775 | 31,17 | 12,39 | 11 114 | 46 772 | |
2019-03-12 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −11 227 | 938 526 | −1,18 | 87,21 | −979 129 | 81 850 730 |
2019-03-12 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −24 400 | 0 | −100,00 | ||||
2019-03-12 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 24 400 | 949 753 | 2,64 | ||||
2019-03-01 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −10 014 | 925 353 | −1,07 | 93,20 | −933 345 | 86 246 601 |
2019-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 575 | 61 725 | −25,00 | ||||
2019-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 575 | 935 367 | 2,25 | ||||
2019-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 169 | 914 792 | −0,99 | 95,07 | −871 734 | 86 972 935 |
2019-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 37 248 | 37 248 | |||||
2019-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 34 110 | 34 110 | |||||
2019-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 025 | 20 025 | −50,00 | ||||
2019-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 025 | 923 961 | 2,22 | ||||
2019-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −16 400 | 903 936 | −1,78 | 90,55 | −1 485 036 | 81 852 309 |
2019-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −34 325 | 68 650 | −33,33 | ||||
2019-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 34 325 | 920 336 | 3,87 | ||||
2019-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −23 236 | 886 011 | −2,56 | 82,49 | −1 916 668 | 73 084 389 |
2019-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −181 250 | 909 247 | −16,62 | 81,90 | −14 844 194 | 74 466 420 |
2019-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −36 453 | 1 090 497 | −3,23 | 80,78 | −2 944 783 | 88 093 619 |
2019-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −28 605 | 1 126 950 | −2,48 | 79,89 | −2 285 339 | 90 035 416 |
2019-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −34 853 | 1 155 555 | −2,93 | 78,80 | −2 746 416 | 91 057 734 |
2019-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Performance Share Units |
M - Exercise | −304 397 | 0 | −100,00 | ||||
2019-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 304 397 | 1 190 408 | 34,36 | ||||
2019-01-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Performance Share Units |
A - Award | 304 397 | 304 397 | |||||
2018-11-14 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −163 514 | 0 | −100,00 | ||||
2018-11-14 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −163 514 | 886 011 | −15,58 | 69,00 | −11 282 466 | 61 134 759 |
2018-11-14 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 163 514 | 1 049 525 | 18,46 | 0,83 | 135 717 | 871 106 | |
2018-11-14 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 3 572 | 886 011 | 0,40 | 5,95 | 21 253 | 5 271 765 | |
2018-07-02 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock, par value $0.0001 |
A - Award | 2 878 | 2 878 | 13,55 | 38 997 | 38 997 | ||
2018-05-31 |
|
4 | EPZM |
Epizyme, Inc.
Stock Option (Right to Buy) |
A - Award | 12 500 | 12 500 | |||||
2018-03-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −11 459 | 882 439 | −1,28 | 52,19 | −598 091 | 46 058 021 |
2018-03-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −24 400 | 24 400 | −50,00 | ||||
2018-03-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 24 400 | 893 898 | 2,81 | ||||
2018-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 82 300 | 82 300 | |||||
2018-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 68 300 | 68 300 | |||||
2018-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 085 | 869 498 | −1,03 | 44,10 | −400 630 | 38 343 123 |
2018-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 025 | 40 050 | −33,33 | ||||
2018-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 025 | 878 583 | 2,33 | ||||
2018-02-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −25 319 | 858 558 | −2,86 | 42,34 | −1 071 956 | 36 349 629 |
2018-02-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −19 500 | 0 | −100,00 | ||||
2018-02-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 500 | 883 877 | 2,26 | ||||
2018-02-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −34 325 | 102 975 | −25,00 | ||||
2018-02-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 34 325 | 864 377 | 4,14 | ||||
2018-02-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −101 488 | 163 514 | −38,30 | ||||
2018-02-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −9 458 | 830 052 | −1,13 | 46,29 | −437 839 | 38 425 597 | |
2018-02-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −50 504 | 839 510 | −5,67 | 46,54 | −2 350 456 | 39 070 795 | |
2018-02-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −41 526 | 890 014 | −4,46 | 44,60 | −1 851 977 | 39 692 844 | |
2018-02-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | X | 101 488 | 931 540 | 12,23 | 0,83 | 84 235 | 773 178 |
2018-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −110 439 | 265 002 | −29,42 | ||||
2018-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −30 036 | 830 052 | −3,49 | 51,66 | −1 551 660 | 42 880 486 | |
2018-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −41 588 | 860 088 | −4,61 | 50,72 | −2 109 427 | 43 625 384 | |
2018-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −26 738 | 901 676 | −2,88 | 49,54 | −1 324 707 | 44 672 636 | |
2018-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −12 077 | 928 414 | −1,28 | 48,87 | −590 167 | 45 368 807 | |
2018-01-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | X | 110 439 | 940 491 | 13,31 | 0,83 | 91 664 | 780 608 |
2018-01-17 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −125 402 | 375 441 | −25,04 | ||||
2018-01-17 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −25 912 | 830 052 | −3,03 | 53,24 | −1 379 659 | 44 195 289 | |
2018-01-17 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −99 490 | 855 964 | −10,41 | 52,68 | −5 240 934 | 45 090 472 | |
2018-01-17 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | X | 125 402 | 955 454 | 15,11 | 0,83 | 104 084 | 793 027 |
2017-12-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −123 512 | 500 843 | −19,78 | ||||
2017-12-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −27 065 | 830 052 | −3,16 | 53,36 | −1 444 053 | 44 287 424 |
2017-12-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −96 447 | 857 117 | −10,11 | 52,37 | −5 050 736 | 44 885 503 |
2017-12-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 123 512 | 953 564 | 14,88 | 0,83 | 102 515 | 791 458 | |
2017-12-08 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −121 849 | 624 355 | −16,33 | ||||
2017-12-08 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −28 370 | 830 052 | −3,30 | 53,80 | −1 526 448 | 44 660 948 |
2017-12-08 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −93 479 | 858 422 | −9,82 | 53,35 | −4 986 731 | 45 793 380 |
2017-12-08 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 121 849 | 951 901 | 14,68 | 0,83 | 101 135 | 790 078 | |
2017-11-22 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −134 057 | 746 204 | −15,23 | ||||
2017-11-22 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −134 057 | 830 052 | −13,90 | 59,50 | −7 976 660 | 49 389 754 |
2017-11-22 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 134 057 | 964 109 | 16,15 | 0,83 | 111 267 | 800 210 | |
2017-11-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −137 815 | 880 261 | −13,54 | ||||
2017-11-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −5 424 | 830 052 | −0,65 | 60,05 | −325 690 | 49 841 302 |
2017-11-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −80 405 | 835 486 | −8,78 | 59,43 | −4 778 550 | 49 653 768 |
2017-11-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −51 976 | 915 891 | −5,37 | 58,59 | −3 045 430 | 53 664 801 |
2017-11-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 137 815 | 967 867 | 16,60 | 0,83 | 114 386 | 803 330 | |
2017-08-17 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −9 242 | 96 758 | −8,72 | ||||
2017-08-17 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 9 242 | 830 052 | 1,13 | 10,82 | 99 998 | 8 981 163 | |
2017-07-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 137 300 | 137 300 | |||||
2017-07-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 240 000 | 240 000 | |||||
2017-07-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 3 571 | 820 810 | 0,44 | 5,95 | 21 247 | 4 883 820 | |
2017-03-14 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −12 059 | 817 239 | −1,45 | 21,16 | −255 168 | 17 292 777 |
2017-03-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −24 400 | 48 800 | −33,33 | ||||
2017-03-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 24 400 | 829 298 | 3,03 | ||||
2017-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −19 557 | 804 898 | −2,37 | 21,48 | −420 084 | 17 289 209 |
2017-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 025 | 60 075 | −25,00 | ||||
2017-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 025 | 824 455 | 2,49 | ||||
2017-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −19 500 | 19 500 | −50,00 | ||||
2017-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 500 | 804 430 | 2,48 | ||||
2017-02-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −7 577 | 784 930 | −0,96 | 21,57 | −163 436 | 16 930 940 |
2017-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −19 375 | 0 | −100,00 | ||||
2017-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 375 | 792 507 | 2,51 | ||||
2017-02-07 |
|
4 | EPZM |
Epizyme, Inc.
Stock Option (Right to Buy) |
A - Award | 25 000 | 25 000 | |||||
2016-11-15 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −33 075 | 94 425 | −25,94 | ||||
2016-11-15 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 33 075 | 773 132 | 4,47 | 9,07 | 299 990 | 7 012 307 | |
2016-11-15 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −275 000 | 740 057 | −27,09 | 17,36 | −4 774 000 | 12 847 390 | |
2016-11-15 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −275 000 | 1 015 057 | −21,32 | 17,52 | −4 818 000 | 17 783 799 | |
2016-11-15 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −600 000 | 1 018 076 | −37,08 | ||||
2016-11-15 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | −50 000 | 1 290 057 | −3,73 | 17,68 | −884 000 | 22 808 208 | |
2016-11-15 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 600 000 | 1 340 057 | 81,07 | 0,83 | 498 000 | 1 112 247 | |
2016-07-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −25 000 | 0 | −100,00 | ||||
2016-07-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 25 000 | 740 057 | 3,50 | ||||
2016-07-27 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 2 750 | 715 057 | 0,39 | 5,95 | 16 362 | 4 254 589 | |
2016-03-11 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −24 400 | 73 200 | −25,00 | ||||
2016-03-11 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 24 400 | 712 307 | 3,55 | ||||
2016-03-11 |
|
4/A | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 80 100 | 80 100 | |||||
2016-03-11 |
|
4/A | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 247 300 | 247 300 | |||||
2016-03-11 |
|
4/A | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −6 895 | 637 907 | −1,07 | 5,81 | −40 060 | 3 706 240 |
2016-03-01 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
P - Purchase | X | 50 000 | 687 907 | 7,84 | 5,00 | 250 000 | 3 439 535 |
2016-02-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −6 895 | 637 907 | −1,07 | 5,81 | −40 060 | 3 706 240 |
2016-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −19 500 | 39 000 | −33,33 | ||||
2016-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 500 | 644 802 | 3,12 | ||||
2016-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −6 866 | 625 302 | −1,09 | 6,39 | −43 874 | 3 995 680 |
2016-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −19 375 | 19 375 | −50,00 | ||||
2016-02-24 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 375 | 632 168 | 3,16 | ||||
2016-01-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −265 924 | 1 618 076 | −14,11 | ||||
2016-01-13 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 265 924 | 612 973 | 76,62 | 0,83 | 220 717 | 508 768 | |
2016-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −10 750 | 346 869 | −3,01 | 8,72 | −93 740 | 3 024 698 |
2016-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 466 | 0 | −100,00 | ||||
2016-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 466 | 357 619 | 6,07 | ||||
2016-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −787 | 337 153 | −0,23 | ||||
2016-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −340 | 337 940 | −0,10 | ||||
2016-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −1 000 | 338 280 | −0,29 | ||||
2016-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −395 | 339 280 | −0,12 | ||||
2015-12-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −81 000 | 1 884 000 | −4,12 | ||||
2015-12-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 81 000 | 338 335 | 31,48 | 0,83 | 67 230 | 280 818 | |
2015-07-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −11 386 | 257 335 | −4,24 | 24,04 | −273 719 | 6 186 333 |
2015-07-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −25 000 | 25 000 | −50,00 | ||||
2015-07-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 25 000 | 268 721 | 10,26 | ||||
2015-07-28 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 1 195 | 244 061 | 0,49 | 17,78 | 21 247 | 4 339 405 | |
2015-03-11 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 97 600 | 97 600 | |||||
2015-03-11 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 71 000 | 71 000 | |||||
2015-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −8 425 | 243 866 | −3,34 | 23,44 | −197 482 | 5 716 219 |
2015-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −19 500 | 58 500 | −25,00 | ||||
2015-02-26 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 500 | 252 291 | 8,38 | ||||
2015-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 798 | 232 791 | −4,04 | 22,90 | −224 374 | 5 330 914 |
2015-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −19 375 | 38 750 | −33,33 | ||||
2015-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 375 | 242 589 | 8,68 | ||||
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 484 | 223 214 | −4,08 | 26,72 | −253 412 | 5 964 278 |
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 467 | 20 466 | −50,00 | ||||
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 467 | 232 698 | 9,64 | ||||
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −1 025 | 212 231 | −0,48 | ||||
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −583 | 213 256 | −0,27 | ||||
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | 65 189 | 65 189 | |||||
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −65 189 | 213 839 | −23,36 | ||||
2015-01-05 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −1 535 | 279 028 | −0,55 | ||||
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | −135 000 | 1 965 000 | −6,43 | ||||
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | X | −133 334 | 2 100 000 | −5,97 | |||
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 135 000 | 280 563 | 92,74 | 0,83 | 112 050 | 232 867 | |
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −133 334 | 145 563 | −47,81 | 23,93 | −3 190 989 | 3 483 657 |
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | X | 133 334 | 278 897 | 91,60 | 0,83 | 110 667 | 231 485 |
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | X | −133 333 | 2 233 334 | −5,63 | |||
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −133 333 | 145 563 | −47,81 | 23,68 | −3 157 632 | 3 447 267 |
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | X | 133 333 | 278 896 | 91,60 | 0,83 | 110 666 | 231 484 |
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
M - Exercise | X | −133 333 | 2 366 667 | −5,33 | |||
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −133 333 | 145 563 | −47,81 | 22,84 | −3 045 566 | 3 324 921 |
2014-10-20 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | X | 133 333 | 278 896 | 91,60 | 0,83 | 110 666 | 231 484 |
2014-07-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −25 000 | 50 000 | −33,33 | ||||
2014-07-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −11 336 | 145 563 | −7,23 | 15,99 | −181 263 | 2 327 552 |
2014-07-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 25 000 | 156 899 | 18,95 | ||||
2014-07-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 2 721 | 131 899 | 2,11 | 7,81 | 21 251 | 1 030 131 | |
2014-06-20 |
|
5 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −4 092 | 118 511 | −3,34 | ||||
2014-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 78 000 | 78 000 | |||||
2014-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 110 000 | 110 000 | |||||
2014-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −8 708 | 134 374 | −6,09 | 14,07 | −122 522 | 1 890 642 |
2014-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 19 375 | 143 082 | 15,66 | ||||
2014-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −9 271 | 123 707 | −6,97 | 11,96 | −110 881 | 1 479 536 |
2014-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
S - Sale | X | −17 108 | 112 511 | −13,20 | 11,96 | −204 612 | 1 345 632 |
2014-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −20 467 | 40 933 | −33,33 | ||||
2014-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 61 400 | 61 400 | |||||
2014-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −37 767 | 0 | −100,00 | ||||
2014-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 20 467 | 132 978 | 18,19 | ||||
2014-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 37 767 | 129 619 | 41,12 | ||||
2013-07-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 75 000 | 75 000 | |||||
2013-07-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 5 082 | 91 852 | 5,86 | 7,81 | 39 690 | 717 364 | |
2013-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 77 500 | 77 500 | |||||
2013-02-25 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 106 000 | 106 000 | |||||
2013-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −37 767 | 37 768 | −50,00 | ||||
2013-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −16 410 | 86 770 | −15,90 | 10,59 | −173 782 | 918 894 | |
2013-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 37 767 | 103 180 | 57,74 | ||||
2013-01-03 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −1 500 | 65 413 | −2,24 | ||||
2012-11-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
P - Purchase | 2 000 | 66 913 | 3,08 | 9,13 | 18 260 | 610 916 | |
2012-11-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 3 277 | 64 913 | 5,32 | 5,48 | 17 958 | 355 723 | |
2012-11-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
A - Award | 2 528 | 61 636 | 4,28 | 5,48 | 13 853 | 337 765 | |
2012-11-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −995 | 59 108 | −1,66 | ||||
2012-11-02 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −2 115 | 60 103 | −3,40 | ||||
2012-02-29 |
|
4 | EXAS |
EXACT SCIENCES CORP
Stock Option (right to buy) |
A - Award | 127 500 | 127 500 | |||||
2012-01-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
M - Exercise | −37 767 | 75 533 | −33,33 | ||||
2012-01-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Restricted Stock Units |
A - Award | 113 300 | 113 300 | |||||
2012-01-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
F - Taxes | −16 410 | 62 218 | −20,87 | 8,12 | −133 249 | 505 210 | |
2012-01-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
M - Exercise | 37 767 | 78 628 | 92,43 | ||||
2012-01-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −2 890 | 40 861 | −6,61 | ||||
2012-01-04 |
|
4 | EXAS |
EXACT SCIENCES CORP
Common Stock |
G - Gift | −2 919 | 43 751 | −6,25 |